Lentiviral FVIII Gene Therapy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03217032 |
Recruitment Status : Unknown
Verified May 2019 by Lung-Ji Chang, Shenzhen Geno-Immune Medical Institute.
Recruitment status was: Not yet recruiting
First Posted : July 13, 2017
Last Update Posted : May 23, 2019
|
Sponsor:
Shenzhen Geno-Immune Medical Institute
Information provided by (Responsible Party):
Lung-Ji Chang, Shenzhen Geno-Immune Medical Institute
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | July 3, 2017 | ||||
First Posted Date ICMJE | July 13, 2017 | ||||
Last Update Posted Date | May 23, 2019 | ||||
Estimated Study Start Date ICMJE | June 1, 2020 | ||||
Estimated Primary Completion Date | May 31, 2022 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Number of participants experiencing drug-related adverse events [ Time Frame: a year ] As assessed by physical exam, vital signs, standard clinical labs, and Bethesda assay for FVIII inhibitor
|
||||
Original Primary Outcome Measures ICMJE |
Number of participants experiencing drug-related adverse events [ Time Frame: a year ] Using CTCAE V4.0 standard to evaluate the level of adverse events after infusion
|
||||
Change History | |||||
Current Secondary Outcome Measures ICMJE |
Changes from baseline in circulating FVIII activity (IU/dL or % normal) [ Time Frame: a year ] | ||||
Original Secondary Outcome Measures ICMJE |
|
||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | Lentiviral FVIII Gene Therapy | ||||
Official Title ICMJE | Lentiviral FVIII Gene Therapy for Hemophilia A | ||||
Brief Summary | This study is a Phase I trial using an advanced lentiviral vector to deliver a functional gene for human clotting factor VIII into patients with hemophilia A, to evaluate the safety and efficacy of infusion of lentiviral gene modified autologous stem cells in patients. | ||||
Detailed Description | Hemophilia A is a genetic bleeding disorder caused by the lack of ability to produce blood-clotting factor VIII (FVIII). Individuals with hemophilia A suffer repeated bleeding episodes, which can cause chronic joint disease and sometimes even death due to the inability for blood to clot efficiently. The current treatment is intravenous infusion of clotting factor concentrates, either prophylactically or in response to bleeding. The procedure is life time long and expensive while still cannot achieve a cure.Gene therapy is a novel technology that has been successfully demonstrated in a number of clinical studies for diseases such as cancer and genetic diseases. In this study, an advanced lentiviral vector system NHP/TYF will be used to deliver a functional FVIII gene to overcome human clotting FVIII gene defect in patients with hemophilia A. This study is a Phase I trial evaluating the safety and efficacy for infusion of gene modified autologous stem cells in patients with hemophilia A. | ||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 1 | ||||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
||||
Condition ICMJE | Hemophilia A | ||||
Intervention ICMJE | Biological: YUVA-GT-F801
Lentiviral factor VIII gene modified autologous hematopoeitic stem cells and mesenchymal stem cells
|
||||
Study Arms ICMJE | Experimental: YUVA-GT-F801
Gene transfer to treat Hemophilia A
Intervention: Biological: YUVA-GT-F801
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Unknown status | ||||
Estimated Enrollment ICMJE |
10 | ||||
Original Estimated Enrollment ICMJE | Same as current | ||||
Estimated Study Completion Date ICMJE | June 1, 2022 | ||||
Estimated Primary Completion Date | May 31, 2022 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 2 Years to 65 Years (Child, Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries ICMJE | China | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT03217032 | ||||
Other Study ID Numbers ICMJE | GIMI-IRB-17007 | ||||
Has Data Monitoring Committee | No | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE |
|
||||
Current Responsible Party | Lung-Ji Chang, Shenzhen Geno-Immune Medical Institute | ||||
Original Responsible Party | Same as current | ||||
Current Study Sponsor ICMJE | Shenzhen Geno-Immune Medical Institute | ||||
Original Study Sponsor ICMJE | Same as current | ||||
Collaborators ICMJE | Not Provided | ||||
Investigators ICMJE |
|
||||
PRS Account | Shenzhen Geno-Immune Medical Institute | ||||
Verification Date | May 2019 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |